FDA ввела строгое предупреждение о риске опасного снижения уровня фосфата при введении препарата Injectafer

Federal Regulators Add Their Strongest Warning to a Common Iron Infusion Over Dangerously Low Phosphate Levels Federal regulators have placed their most prominent safety warning on one of the most widely used intravenous iron treatments in the United States. The Food and Drug Administration approved labeling revisions for ferric carboxymaltose injection, sold as Injectafer, adding a boxed warning that describes the risk of symptomatic hypophosphatemia, meaning dangerously low levels of phosphate in the blood. The action affects a drug that people receive in outpatient infusion suites, hematology clinics, cardiology offices, and hospital day units across the country. Injectafer is approved for iron deficiency anemia in patients one year of age and older who cannot tolerate oral iron or who do not fully respond to it, for iron deficiency in adults with non-dialysis-dependent chronic kidney disease, and for iron deficiency in adults with heart failure classified as New York Heart Association class II or III, to improve exercise capacity. For families, the practical consequence is specific rather than abstract. The agency now recommends checking serum phosphate levels before a repeat course in patients at risk of low phosphate, and in any patient receiving another course within three months of the previous one. That is a blood test many patients have never been offered. A Warning That Moves to the Top of the Label A boxed warning is the strongest labeling requirement the FDA can impose short of pulling a product. In its drug safety communication, the agency said clinical effects depend on how severe and how prolonged the phosphate drop is. Reported symptoms include muscle weakness or pain, fatigue, tremors, confusion, seizures and cardiac arrhythmias. Chronic severe hypophosphatemia can lead to osteomalacia, a softening of bone, and to fractures. This is not the agency's first move on the issue. The FDA determined in 2019 that the drug can cause serious symptomatic hypophosphatemia, and a warning was added in February 2020. In May 2023 that warning was revised to add phosphate monitoring recommendations, to name osteomalacia and fractures as possible long term complications, and to list inflammatory bowel disease as a risk factor. The warning was revised again in 2025 to add further risk factors, and those layers are reflected in the current prescribing information. The latest escalation followed a fresh agency assessment that drew on adverse event reports, published literature, and the FDA's Sentinel System. Regulators concluded that symptomatic hypophosphatemia was still being reported despite the earlier label changes. The safety communication was published on September 1. Patients Most Likely to Be Affected Risk is not spread evenly. The people most exposed are those receiving repeat courses, particularly a second course within three months, and those with conditions that already predispose them to phosphate loss. The manufacturer's safety information lists possible risk factors including gastrointestinal disorders associated with malabsorption, inflammatory bowel disease, hyperparathyroidism, vitamin D deficiency, malnutrition and hereditary hemorrhagic telangiectasia. Iron deficiency anemia itself is common in groups that already carry other health burdens. It affects many patients with gastrointestinal disease, people with chronic kidney disease, patients with heart failure, and women with heavy uterine bleeding or postpartum anemia. Because Injectafer is approved down to age one, pediatric patients are also covered by the new labeling. There is a confounding detail that matters at the bedside. The FDA noted that some symptoms of low phosphate can resemble the symptoms of iron deficiency anemia itself. Fatigue and weakness are the obvious overlap. A patient who feels worn out after an infusion may reasonably assume the anemia has not improved yet, when the cause could be something else entirely. The Monitoring Gap Behind the Decision The most striking figure in the agency's assessment is not about the drug. It is about follow-up. Data from the FDA's Sentinel System indicate that serum phosphate laboratory testing occurs in fewer than 20 percent of ferric carboxymaltose administration episodes. That means the recommended safety check was skipped in the large majority of infusions, seven years after the agency first determined the risk was real and three years after monitoring language was written into the label. The FDA said the adverse event case series included reports following both single and multiple infusions, and that consequences included hospitalization, phosphate replacement therapy lasting weeks to months, and extensive monitoring with regular follow-up visits. The agency's own framing is that this harm is largely preventable. Regulators wrote that the adverse reaction can be prevented or reduced in severity through appropriate phosphate monitoring and early intervention, and that the boxed warning highlights guidance already present in the labeling. Readers can track future actions of this kind through the agency's safety communication archive. Certain strengths of the drug are also sold as generic ferric carboxymaltose. Generic application holders are expected to update their own labeling to match. Questions Worth Raising Before the Next Infusion Patients should not stop or delay treatment on their own. Iron deficiency anemia has real consequences, and this labeling change is about monitoring rather than withdrawal. The FDA advises patients to immediately report new or worsening symptoms of low phosphate to a health care professional, naming muscle weakness or pain, fatigue, bone and joint pain, and confusion. Anyone experiencing seizures, an irregular heartbeat, chest pain or a sudden change in alertness should seek urgent medical care. Before a scheduled infusion, it is reasonable to ask whether a phosphate level has been checked, whether this counts as a repeat course within three months, and whether any personal risk factors apply. Clinicians are advised to correct existing low phosphate before administering the drug, to monitor patients at risk of chronic low phosphate, and to consider permanent discontinuation for severe symptomatic or persistent cases. Patients and clinicians can report problems through the FDA MedWatch program. Cost is a live question for some households, since a phosphate panel adds a lab charge, though basic metabolic testing is generally covered by insurance and by Medicare when ordered for a clinical reason. People facing coverage denials can ask a provider about appeals or about manufacturer patient assistance. Those who want to hear about future changes first can sign up for the agency's email alerts on drug safety. What remains unresolved is how quickly infusion practice will change. The FDA has not published a target monitoring rate, and no timeline has been announced for reassessing whether testing improves. Key Questions Answered What did the FDA actually change? The agency approved labeling revisions adding a boxed warning, its most prominent safety warning, describing the risk of symptomatic hypophosphatemia with ferric carboxymaltose injection. Is the drug being recalled or withdrawn? No. Injectafer remains approved and available. The change concerns warnings and monitoring, not market removal. Who faces the highest risk? Patients receiving a repeat course within three months, those with existing risk factors for low phosphate, and patients with conditions such as inflammatory bowel disease. What symptoms should prompt a call? Muscle weakness or pain, fatigue, bone and joint pain, and confusion. Seizures, irregular heartbeat, or sudden confusion warrant urgent evaluation. Why is this confusing to spot? The FDA noted that some low phosphate symptoms mimic the symptoms of iron deficiency anemia, which is the condition the infusion is treating. What is the monitoring recommendation? Check serum phosphate before a repeat course in at-risk patients and in anyone receiving another course within three months, and correct low phosphate before administering the drug. Does this apply to generic versions? Generic application holders of ferric carboxymaltose injection are expected to update their labeling to incorporate the change. Published by Medicaldaily.com